Enhancement of ambulation-increasing effect of methamphetamine by peripherally-administered 6R-L-erythro-5,6,7,8-tetrahydrobiopterin (R-THBP) in mice.

Asami, Takayasu; Kuribara, Hisashi

doi:10.1254/jjp.50.175

Cited by 10 publications

(6 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it is interesting that R-THBP did not en hance the ambulatory increment by ketamine. R-THBP was reported to markedly augment the effect of methamphetamine, which was intimately connected with the newly synthesized dopamine (34). It is prob able that ketamine stimulates the dopamine release, but hardly affects the dopamine synthesis, unlike metham phetamine.…”

Section: Discussionmentioning

confidence: 89%

Assessment of the Ambulation-Increasing Effect of Ketamine by Coadministration with Central-Acting Drugs in Mice.

1992

Self Cite

View full text Add to dashboard Cite

ABSTRACT-The coadministration of ketamine (12.5 mg/kg, but not 3.1 mg/kg, s.c.) with metham phetamine (2 mg/kg, s.c.), cocaine (10 mg/kg, s.c.), scopolamine (0.5 mg/kg, s.c.), caffeine (10 mg/kg, s.c.) and MK-801 (0.1 mg/kg, i.p.) significantly enhanced the ambulation-increasing effects. Further more, in the coadministration with morphine (10 mg/kg, s.c.) and GBR-12909 (10 mg/kg, i.p.), not only 12.5 mg/kg but also 3.1 mg/kg of ketamine produced a significant enhancement. On the other hand, the ambulation-increasing effect of ketamine (12.5 mg/kg, s.c.) was significantly suppressed by ceruletide (0.01 mg/kg, i.p.), a-methyl-p-tyrosine (100 and 300 mg/kg, i.p. X 2), nimodipine (1 and 3 mg/kg, i.p.), haloperidol (0.03 and 0.1 mg/kg, s.c.), a low dose of apomorphine (0.1 mg/kg, s.c.), phy sostigmine (0.1 mg/kg, s.c.) and N6-(L-2-phenylisopropyl)-adenosine (0.1 mg/kg, s.c.). However, imipramine (20 mg/kg, i.p.), 6R-L-erythro-5,6,7,8-tetrahydrobiopterin (100 mg/kg, s.c.), a high dose of apomorphine (0.5 mg/kg), reserpine (0.3 and 1 mg/kg, s.c.), propranolol (0.3 and 1 mg/kg, s.c.), phe noxybenzamine (3 and 10 mg/kg, s.c.) and naloxone (0.3 and 1 mg/kg, s.c.) scarcely interacted with ketamine. These results suggest that ketamine increases the ambulatory activity in mice by facilitating dopamine release from a newly synthesized pool at the presynaptic level, which is affected by a calcium-dependent mechanism.

show abstract

Section: Discussionmentioning

confidence: 89%

Assessment of the Ambulation-Increasing Effect of Ketamine by Coadministration with Central-Acting Drugs in Mice.

1992

Self Cite

View full text Add to dashboard Cite

show abstract

“…Imipramine and R THBP enhanced the ambulation-increasing effect of methamphetamine, cocaine and/or GBR-12909 even though the tested doses of these 3 drugs were subeffective or effective (11,19). Furtheremore, 0.1 mg/kg of MK-801, which was a subeffective dose for increasing the mouse's ambulatory activity, did not show any interaction with the drugs mentioned above.…”

Section: The Coadministrationmentioning

confidence: 83%

Characteristics of the Ambulation-Increasing Effect of the Noncompetitive NMDA Antagonist MK-801 in Mice: Assessment by the Coadministration with Central-Acting Drugs.

Kuribara¹,

Asami

Ida

et al. 1992

Jpn.J.Pharmacol

Self Cite

View full text Add to dashboard Cite

ABSTRACT-Characteristics of the ambulation-increasing effect of MK-801, a non competitive NMDA antagonist, were assessed through the coadministration of MK 801 with various central-acting drugs in mice. The MK-801 (0.3 mg/kg, i.p.)-induced ambulation-increment with a slight ataxia was maximum at around 50 min, and ambulation returned to the control level at about 3 hr after the administration. At 1 mg/kg, the mouse's activity transiently increased, followed by a decrease due to a marked ataxia, which was due to neither stereotypy nor convulsion, for 20-50 min, and then increased again; the ambulation-increment continued even at 4 hr after the administration. Coadministration of MK-801 (0.3 mg/kg, i.p.) with either methampheta mine (2 mg/kg, s.c.), cocaine (20 mg/kg, s.c.), GBR-12909 (10 mg/kg, i.p.), scopol amine (0.5 mg/kg, s.c.), caffeine (10 mg/kg, s.c.) or morphine (10 mg/kg, s.c.) pro duced a significant enhancement of the effect. However, 0.1 mg/kg of MK-801 had no effect on the interaction with these drugs. On the other hand, the ambulation-increas ing effect of MK-801 (0.3 mg/kg) was significantly reduced by haloperidol (0.03 and 0.1 mg/kg, s.c.), ceruletide (0.01 and 0.1 mg/kg, i.p.), reserpine (0.05 and 2 mg/kg, s.c., pretreatment 4 hr before) and nimodipine (1 and 3 mg/kg, i.p.), but it was scarcely modified by a-methyl-p-tyrosine (100 and 200 mg/kg, i.p., pretreatment 24 hr and 4 hr before), imipramine (20 mg/kg, i.p.), 6R-L-erythro-5,6,7,8-tetrahydro-bio pterin (100 mg/kg, i.p.), pilocarpine (1 and 4 mg/kg, s.c.), N6-(L-2-phenylisopropyl) adenosine (0.03 and 0.1 mg/kg, s.c.) and naloxone (1 and 5 mg/kg, s.c.). These re sults indicate the MR-801 increases the mouse's ambulatory activity through stimula tion of the dopaminergic system which is strongly affected by a calcium-dependent mechanism.The noncompetitive NMDA antagonist MK 801, (+)-5-methyl-10,11-dihydro-5H-dibenzo [a,d]cyclohepten-5,10-imine (1), has been re ceiving much attention in behavioral pharma cology as a tool for assessing the role of the central neurotransmission systems of the NMDA-component.It has been reported that MK-801 shows anticonvulsant action (2), neuroprotective ac tion (3), an antiparkinson property (4), and anticonflict action (5, 6). Furthermore, Clineschmidt et al. (7) demonstrated that MK

show abstract

“…On the other hand, R-THBP enhanced the ambulation-increasing effect of GBR, simi lar to methamphetamine. We have demon strated that R-THBP produces no significant change in the effect of cocaine (21). Further more, the modifications by various drugs of the ambulation-increasing effect of GBR sug gest that GBR may interact, probably indirect ly, with noradrenergic, cholinergic and adeno sine systems, etc.…”

Section: Discussionmentioning

confidence: 75%

“…GBR was effective for enhancing the ambulation-increasing effects of all these drugs. R-THBP acts as a coenzyme for tyrosine hydroxylase (20), and it markedly enhances the ambulation-increasing effect of methamphetamine (21). This com pound also enhanced the effect of GBR.…”

Section: Discussionmentioning

confidence: 91%

Characteristics of the Ambulation-Increasing Effect of GBR-12909, a Selective Dopamine Uptake Inhibitor, in Mice.

Hirate

Kuribara

1991

Jpn.J.Pharmacol

Self Cite

View full text Add to dashboard Cite

ABSTRACT-Behavioral effects of a dopamine uptake inhibitor, GBR-12909 (GBR), were evaluated by ambulatory activity in mice. The single administration of over 10 mg/kg of GBR, i.p. and p.o., significantly increased the ambulatory activity. The re peated administration of GBR, at only 10 mg/kg, produced a reverse tolerance to its ambulation-increasing effect. However, a cross-reverse tolerance was induced between GBR (10 and 20 mg/kg) and methamphetamine (2 mg/kg) in both directions. Further more, 5 mg/kg of GBR significantly enhanced the effects of methamphetamine, cocaine, imipramine, morphine, scopolamine and caffeine. R-THBP, a coenzyme of tyrosine hydroxylase, also enhanced the effect of GBR. In contrast, the ambulation increasing effect of 10 mg/kg of GBR was markedly reduced by haloperidol, chlor promazine, tetrabenazine, oxypertine, reserpine and a -methyl-p-tyrosine. On the other hand, the effect of GBR was only slightly and/or scarcely modified by apomor phine, caerulein, physostigmine, pilocarpine, N6-(L-2-phenylisopropyl)-adenosine and naloxone. The neurochemical experiment in rats, not in mice, revealed that GBR pos sessed more dominant action on dopaminergic systems than noradrenergic or sero tonergic systems. However, the behavioral characteristics of GBR are similar to those of methamphetamine and cocaine, which possess less selective action than GBR on dopaminergic and noradrenergic systems. Dopaminergic and noradrenergic neurons in the central nervous system play important roles in the behavioral effects of drugs. Methamphetamine and cocaine are com pounds which act as central stimulants through an acceleration of release and/or an inhibition of uptake of dopamine (DA) and norepi nephrine (NE) (1). In the animal experiments, methamphetamine and cocaine both increase ambulatory activity at comparatively lower doses, and they produce stereotyped behaviors at higher doses (2). Furthermore, it has been well-known that the repeated administration of methamphetamine or cocaine produces re verse tolerances to its ambulation-increasing and stereotypy-producing effects (3-5). The dopaminergic systems have been considered to play an important role in the development of reverse tolerance to amphetamines and their related drugs (4). There are many DA and NE-uptake inhibitors, such as nomifensine, methylphenidate and mazindol, and their be havioral effects resemble those of metham phetamine and cocaine (2). However, these compounds lack selectivity for either norad renergic or dopaminergic neuron.

show abstract

Enhancement of ambulation-increasing effect of methamphetamine by peripherally-administered 6R-L-erythro-5,6,7,8-tetrahydrobiopterin (R-THBP) in mice.

Cited by 10 publications

References 29 publications

Assessment of the Ambulation-Increasing Effect of Ketamine by Coadministration with Central-Acting Drugs in Mice.

Assessment of the Ambulation-Increasing Effect of Ketamine by Coadministration with Central-Acting Drugs in Mice.

Characteristics of the Ambulation-Increasing Effect of the Noncompetitive NMDA Antagonist MK-801 in Mice: Assessment by the Coadministration with Central-Acting Drugs.

Characteristics of the Ambulation-Increasing Effect of GBR-12909, a Selective Dopamine Uptake Inhibitor, in Mice.

Contact Info

Product

Resources

About